Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.01.2023 | Case report

Eltrombopag/glucocorticoids/immune-globulin

No response and rebound effect: 2 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Diaz Jordan B, et al. Loss of response after discontinuation of eltrombopag in a patient with immune thrombocytopenia secondary to COVID-19: another finding of persistent COVID syndrome ?. Research and Practice in Thrombosis and Haemostasis 6 (Spec. issue 1): abstr. PO0010, Oct 2022. Available from: URL: http://doi.org/10.1002/rth2.12789 [abstract] Diaz Jordan B, et al. Loss of response after discontinuation of eltrombopag in a patient with immune thrombocytopenia secondary to COVID-19: another finding of persistent COVID syndrome ?. Research and Practice in Thrombosis and Haemostasis 6 (Spec. issue 1): abstr. PO0010, Oct 2022. Available from: URL: http://​doi.​org/​10.​1002/​rth2.​12789 [abstract]
Metadaten
Titel
Eltrombopag/glucocorticoids/immune-globulin
No response and rebound effect: 2 case reports
Publikationsdatum
01.01.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-30726-x

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Multiple drugs

Case report

Multiple drugs

Case report

Amiodarone